Traditionally D-dimer is elevated when there are fibrin degradation products associated with clots. But D dimer is also elevated in other inflammatory conditions, trauma, post-op state / malignancy.
In COVID-19, its role is primarily as a marker of severity & inflammation.
2/10
Studies in COVID-19 patients have shown that unless there are specific clinical pointers to a clot (leg or lung), an elevated D-dimer value ALONE will not be worth pursuing: we might end up chasing a bird that was never there.
3/10
This study proves exactly that. In many COVID-19 patients, D-dimer is simply a marker of the ongoing inflammation, rather than the signal of a "hidden clot somewhere".
For that reason, it is unwise to depend on an isolated D-dimer value alone to decide on anticoagulation.
4/10
It is also observed that among patients who are admitted to hospital with COVID-19, an elevated D dimer at admission has predictive or prognostic value.
The obvious question comes up now:
How good is the link between PE (pulmonary embolism) and D dimer?
5/10
The relationship is interesting, and invokes the concept of PPV (positive predictive value). In someone with high pretest probability of PE, a high D dimer will help in the diagnosis.
This is called PPV. That is the ability of a positive test to predict the disease.
6/10
In other words, in this context PPV means, out of a 100 positive D dimer tests, how many had PE?
PPV is different from sensitivity - ability of a test to turn positive when done on a diseased person. That is, out of 100 people with PE, how many can the Ddimer test pick up?
7/10
PPV is not fixed - for any test. It varies depending on the clinical setting.
It is like saying, if you hear someone knocking on your door at 9 in the morning, it is likely to be someone you need to meet. But if the same knock occurs at 3 AM, it probably means trouble.
8/10
Likewise, the same test could mean different things depending on the context it was ordered in. In summary, a high D dimer value alone may not mean anything in a COVID patient who is otherwise doing well.
Often, it is good to leave well enough alone.
Linking my article.
9/10
Knowledge of biostatistics is essential in healthcare.
Attaching my article from 3 years ago, written in the context of the tread mill test (TMT) & heart disease, but as an easy teaching example of interpreting the fundamentals of ordering tests.
Covaxin tested against two variants B.1.617.2 (India) & B.1.351 (S Africa). Mild reduction in neutralization ability noted; 2.7 and 3-fold, which is a smaller loss compared to other vaccines, reports ICMR/NIV study.
See graph for comparison.
Thread. 1/n biorxiv.org/content/10.110…
Neutralizing ability is one of the parameters scientists use to measure a vaccine's firepower against a virus.
If the vaccine is very effective, then its ability will be 1 or close to 1 -that is, in comparison with how effective the same vaccine was against the old virus.
2/12
If the virus has become so smart, it will then take several times the original "neutralising power" to kill it.
e.g. If the amount of vaccine required to kill the new variant is 10 times what it took to kill the old virus, we say the neutralising ability is 10-fold lower.
Traditionally we hear about virus entering the exposed surface of the cell, like a bug flying in through the open window of a multi-apartment complex.
Now, imagine this bug burrowing through the walls into all the neighboring units. That essentially is cell-to-cell entry.
2/4
The problem with this process is that our neutralising antibodies might not be able to stop it.
These antibodies are designed to stop the bug from entering through the window, but not from burrowing through the walls between adjacent apartments.
3/4
ICMR-NIV study on P.2, the variant originally found in Brazil since ~April 2020 (WHO). Also called B.1.1.28.2 or zeta, it is now being rapidly replaced by P.1 in Brazil.
ICMR/NIV observed its effects on hamsters in comparison with P.1.
Presenting some context first. This variant P.2 was only seen in 2 samples so far in India; from asymptomatic travelers who arrived from Brazil and UK.
In Brazil, it is also being phased out by P.1 (deeper colour in recent weeks of 2021, genomic data from Manaus, Brazil).
2/13
Study from Brazil showing how P.2 is being phased out by P.1. The latter variant has the N501Y mutation in addition to E484K, among several others.
The latest COVID-19 guideline from Directorate General of Health Services at Ministry of Health & Family Welfare @MoHFW_INDIA, are pristine no-nonsense science.
Antibody titre 115 AU/ml for Covishield and 51 for covaxin.
27 breakthrough infections occurred (4.9%) after both doses: 25 were mild, 2 were moderate, no deaths.
Risk of breakthrough infection:
5.5% with covishield
2.2% with covaxin
2/5
Listing some facts which will help understand the context of the study:
1. Anti Spike antibody is not the same as neutralising antibody. Its level is not known to reliably correlate with NAb, which is typically measured only in research labs. See my earlier tweet on this.
3/5